These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 8632328)

  • 1. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
    Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
    J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.
    Ohlstein EH; Nambi P; Hay DW; Gellai M; Brooks DP; Luengo J; Xiang JN; Elliott JD
    J Pharmacol Exp Ther; 1998 Aug; 286(2):650-6. PubMed ID: 9694916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
    Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonist-dependent inhibition by peptide and nonpeptide endothelin receptor antagonists in the rabbit isolated pulmonary artery.
    Beck GR; Douglas SA; Elliott JD; Ohlstein EH
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S385-8. PubMed ID: 8587422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptors.
    Nambi P; Pullen M; Wu HL; Lee D; Saunders D; Heys R; Aiyar N; Leber J; Elliott J; Brooks D; Ohlstein E; Ruffolo R
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1567-71. PubMed ID: 8667224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670.
    Ohlstein EH; Beck GR; Douglas SA; Nambi P; Lago MA; Gleason JG; Ruffolo RR; Feuerstein G; Elliott JD
    J Pharmacol Exp Ther; 1994 Nov; 271(2):762-8. PubMed ID: 7965794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist.
    Hoshino T; Yamauchi R; Kikkawa K; Yabana H; Murata S
    J Pharmacol Exp Ther; 1998 Aug; 286(2):643-9. PubMed ID: 9694915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.
    Opgenorth TJ; Adler AL; Calzadilla SV; Chiou WJ; Dayton BD; Dixon DB; Gehrke LJ; Hernandez L; Magnuson SR; Marsh KC; Novosad EI; Von Geldern TW; Wessale JL; Winn M; Wu-Wong JR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):473-81. PubMed ID: 8632312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of two novel mixed ETA/ETB receptor antagonists, BQ-928 and 238, in the carotid and pulmonary arteries and the perfused kidney of the rabbit.
    Maurice MC; Gratton JP; D'Orléans-Juste P
    Br J Pharmacol; 1997 Jan; 120(2):319-25. PubMed ID: 9117126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist.
    Williams DL; Murphy KL; Nolan NA; O'Brien JA; Pettibone DJ; Kivlighn SD; Krause SM; Lis EV; Zingaro GJ; Gabel RA
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1518-26. PubMed ID: 8531124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist.
    Reynolds EE; Keiser JA; Haleen SJ; Walker DM; Olszewski B; Schroeder RL; Taylor DG; Hwang O; Welch KM; Flynn MA
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1410-7. PubMed ID: 7791115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships of a novel series of orally active nonpeptide ETA and ETA/B endothelin receptor-selective antagonists.
    Doherty AM; Patt WC; Repine J; Edmunds JJ; Berryman KA; Reisdorph BR; Walker DM; Haleen SJ; Keiser JA; Flynn MA
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S358-61. PubMed ID: 8587414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
    Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic evidence for the presence of three functional endothelin receptor subtypes in rabbit saphenous vein.
    Douglas SA; Beck GR; Elliott JD; Ohlstein EH
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S163-8. PubMed ID: 8587352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a potent and selective endothelin-B receptor antagonist, IRL 2500.
    Balwierczak JL; Bruseo CW; DelGrande D; Jeng AY; Savage P; Shetty SS
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S393-6. PubMed ID: 8587424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
    Clozel M; Breu V; Gray GA; Kalina B; Löffler BM; Burri K; Cassal JM; Hirth G; Müller M; Neidhart W
    J Pharmacol Exp Ther; 1994 Jul; 270(1):228-35. PubMed ID: 8035319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors.
    Willette RN; Sauermelch CF; Storer BL; Guiney S; Luengo JI; Xiang JN; Elliott JD; Ohlstein EH
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S149-57. PubMed ID: 9595425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and binding characterization of endothelin receptors in human bronchus: evidence for a novel endothelin B receptor subtype?
    Hay DW; Luttmann MA; Pullen MA; Nambi P
    J Pharmacol Exp Ther; 1998 Feb; 284(2):669-77. PubMed ID: 9454813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein.
    Douglas SA; Beck GR; Elliott JD; Ohlstein EH
    Br J Pharmacol; 1995 Apr; 114(8):1529-40. PubMed ID: 7599920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the contractile effects and binding kinetics of endothelin-1 and sarafotoxin S6b in rat isolated renal artery.
    Devadason PS; Henry PJ
    Br J Pharmacol; 1997 May; 121(2):253-63. PubMed ID: 9154335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.